Company Information

Company Name *

Company Description *

•Breakthrough technology for cell, tissue ($8.8Bn) and organ preservation ($10Bn) •Enables all regenerative medicine by solving the fundamental legacy problem of preservation •IP -Global protection with issued patents-composition of matter •$11M in government contracts and grants; $10M in-kind and access to $150M facility •Venture-backed company (Series A press release) •FDA Breakthrough Designation •Cell product XT-Thrive®in revenue now (Phase appropriate GMP to full GMP) •Organ product XT-ViVo®+ TimeSeal®buy-in from large transplant centers, OPOs and bipartisan congressional support •Strong DoD contract interests (DPSI, BARDA, MRMC, ARMI) •Global team–San Francisco Bay Area (HQ) and Innsbruck, Austria (1stsubsidiary)

Website

Industry Type

Industry Type BioTherapy Hematology Other Unassigned

Incoming Channel